Brahim Harbaoui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brahim Harbaoui has a total of 177 co-authors. Here are the top co-authors by number of shared publications:
- Pierre-Yves Courand
Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France; Université de Lyon, CREATIS, CNRS UMR5220, INSERM U1044, INSA-Lyon, Université Claude Bernard Lyon 1, Lyon, France
11 shared publications - Pierre Lantelme
Institut de Cardiologie, Hospices Civils de Lyon, Lyon, France; Université de Lyon, CREATIS, CNRS UMR5220, INSERM U1044, INSA-Lyon, Université Claude Bernard Lyon 1, Lyon, France
10 shared publications Pierre Lantelme
Cardiology Department, Hospital Croix-Rousse and Hospital Lyon Sud, Hospices Civils de Lyon, France (M.B., L. Maxo, P.-Y.C., A.B., P.L., B.H.).
8 shared publications- Marc Bonnet
Cardiologie interventionnelle, Centre Hospitalier Annecy Genevois, Annecy, France
7 shared publications H. Milon
6 shared publicationsP.Y. Courand
5 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (11)
Letter by Hayek et al Regarding Article, “RACI: A Novel Prognostic Marker in Functional Tricuspid Regurgitation”
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (11)
Letter by Hayek et al Regarding Article, “RACI: A Novel Prognostic Marker in Functional Tricuspid Regurgitation”
- Open Access
- 27 February 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (8) , 708-711
Modalities and safety of cardiac rehabilitation in a population managed for spontaneous haematoma or coronary disruption: insights from the READAPT-DISCO study
- 27 February 2025
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 32 (8) , 708-711
Open AccessModalities and safety of cardiac rehabilitation in a population managed for spontaneous haematoma or coronary disruption: insights from the READAPT-DISCO study
- 1 July 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (7) , e016814
Comprehensive Assessment and Periprocedural Prognostic Significance of Aortic Tortuosity in Transfemoral Transcatheter Aortic Valve Implantation
- 1 July 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 17 (7) , e016814
Comprehensive Assessment and Periprocedural Prognostic Significance of Aortic Tortuosity in Transfemoral Transcatheter Aortic Valve Implantation
- Open Access
- 5 March 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (5) , e030975
Optimal Heart Failure Medical Therapy and Mortality in Survivors of Cardiogenic Shock: Insights From the FRENSHOCK Registry
Background: The effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied. Thus, this study investigated the association between guideline‐directed heart failure (HF) medical therapy (GDMT) and one‐year survival rate in patients who are post‐CS. Methods and Results: FRENSHOCK (French Observatory on the Management of Cardiogenic Shock in 2016) registry was a prospective multicenter observational survey, conducted in metropolitan French intensive care units and intensive cardiac care units. Of 772 patients, 535 patients were enrolled in the present analysis following the exclusion of 217 in‐hospital deaths and 20 patients with missing medical records. Patients with triple GDMT (beta‐blockers, renin‐angiotensin system inhibitors, and mineralocorticoid receptor antagonists) at discharge (n=112) were likely to have lower left ventricular ejection fraction on admission and at discharge compared with those without triple GDMT (n=423) (22% versus 28%, P P P =0.007). Similarly, 2:1 propensity score matching and inverse probability treatment weighting based on the propensity score demonstrated a lower incidence of one‐year mortality in the triple GDMT group. As the number of HF drugs increased, a stepwise decrease in mortality was observed (log rank; P <0.001). Conclusions: In survivors of CS, the one‐year mortality rate was significantly lower in those with triple GDMT. Therefore, this study suggests that intensive HF therapy should be considered in patients following CS.
- 5 March 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (5) , e030975
Open AccessOptimal Heart Failure Medical Therapy and Mortality in Survivors of Cardiogenic Shock: Insights From the FRENSHOCK Registry
Background: The effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied. Thus, this study investigated the association between guideline‐directed heart failure (HF) medical therapy (GDMT) and one‐year survival rate in patients who are post‐CS. Methods and Results: FRENSHOCK (French Observatory on the Management of Cardiogenic Shock in 2016) registry was a prospective multicenter observational survey, conducted in metropolitan French intensive care units and intensive cardiac care units. Of 772 patients, 535 patients were enrolled in the present analysis following the exclusion of 217 in‐hospital deaths and 20 patients with missing medical records. Patients with triple GDMT (beta‐blockers, renin‐angiotensin system inhibitors, and mineralocorticoid receptor antagonists) at discharge (n=112) were likely to have lower left ventricular ejection fraction on admission and at discharge compared with those without triple GDMT (n=423) (22% versus 28%, P P P =0.007). Similarly, 2:1 propensity score matching and inverse probability treatment weighting based on the propensity score demonstrated a lower incidence of one‐year mortality in the triple GDMT group. As the number of HF drugs increased, a stepwise decrease in mortality was observed (log rank; P <0.001). Conclusions: In survivors of CS, the one‐year mortality rate was significantly lower in those with triple GDMT. Therefore, this study suggests that intensive HF therapy should be considered in patients following CS.
- Open Access
- 13 October 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (46) , 4847-4858
Intra-pocket ultrasound-guided axillary vein puncture vs. cephalic vein cutdown for cardiac electronic device implantation: the ACCESS trial
Intra-pocket ultrasound-guided axillary vein puncture (IPUS-AVP) for venous access in implantation of transvenous cardiac implantable electronic devices (CIED) is uncommon due to the lack of clinical evidence supporting this technique. This study investigated the efficacy and early complications of IPUS-AVP compared to the standard method using cephalic vein cutdown (CVC) for CIED implantation. ACCESS was an investigator-led, interventional, randomized (1:1 ratio), monocentric, controlled superiority trial. A total of 200 patients undergoing CIED implantation were randomized to IPUS-AVP (n = 101) or CVC (n = 99) as a first assigned route. The primary endpoint was the success rate of insertion of all leads using the first assigned venous access technique. The secondary endpoints were time to venous access, total procedure duration, fluoroscopy time, X-ray exposure, and complications. Complications were monitored during a follow-up period of three months after procedure. IPUS-AVP was significantly superior to CVC for the primary endpoint with 100 (99.0%) vs. 86 (86.9%) procedural successes (P = .001). Cephalic vein cutdown followed by subclavian vein puncture was successful in a total of 95 (96.0%) patients, P = .21 vs. IPUS-AVP. All secondary endpoints were also significantly improved in the IPUS-AVP group with reduction in time to venous access [3.4 vs. 10.6 min, geometric mean ratio (GMR) 0.32 (95% confidence interval, CI, 0.28–0.36), P < .001], total procedure duration [33.8 vs. 46.9 min, GMR 0.72 (95% CI 0.67–0.78), P < .001], fluoroscopy time [2.4 vs. 3.3 min, GMR 0.74 (95% CI 0.63–0.86), P < .001], and X-ray exposure [1083 vs. 1423 mGy.cm², GMR 0.76 (95% CI 0.62–0.93), P = .009]. There was no significant difference in complication rates between groups (P = .68). IPUS-AVP is superior to CVC in terms of success rate, time to venous access, procedure duration, and radiation exposure. Complication rates were similar between the two groups. Intra-pocket ultrasound-guided axillary vein puncture should be a recommended venous access technique for CIED implantation. Efficacy and safety of intra-pocket ultrasound-guided axillary vein access vs. cephalic vein cutdown for implantation of cardiac electronic devices. CVC, cephalic vein cutdown; IPUS-AVP, intra-pocket ultrasound-guided axillary vein puncture.
- 13 October 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (46) , 4847-4858
Open AccessIntra-pocket ultrasound-guided axillary vein puncture vs. cephalic vein cutdown for cardiac electronic device implantation: the ACCESS trial
Intra-pocket ultrasound-guided axillary vein puncture (IPUS-AVP) for venous access in implantation of transvenous cardiac implantable electronic devices (CIED) is uncommon due to the lack of clinical evidence supporting this technique. This study investigated the efficacy and early complications of IPUS-AVP compared to the standard method using cephalic vein cutdown (CVC) for CIED implantation. ACCESS was an investigator-led, interventional, randomized (1:1 ratio), monocentric, controlled superiority trial. A total of 200 patients undergoing CIED implantation were randomized to IPUS-AVP (n = 101) or CVC (n = 99) as a first assigned route. The primary endpoint was the success rate of insertion of all leads using the first assigned venous access technique. The secondary endpoints were time to venous access, total procedure duration, fluoroscopy time, X-ray exposure, and complications. Complications were monitored during a follow-up period of three months after procedure. IPUS-AVP was significantly superior to CVC for the primary endpoint with 100 (99.0%) vs. 86 (86.9%) procedural successes (P = .001). Cephalic vein cutdown followed by subclavian vein puncture was successful in a total of 95 (96.0%) patients, P = .21 vs. IPUS-AVP. All secondary endpoints were also significantly improved in the IPUS-AVP group with reduction in time to venous access [3.4 vs. 10.6 min, geometric mean ratio (GMR) 0.32 (95% confidence interval, CI, 0.28–0.36), P < .001], total procedure duration [33.8 vs. 46.9 min, GMR 0.72 (95% CI 0.67–0.78), P < .001], fluoroscopy time [2.4 vs. 3.3 min, GMR 0.74 (95% CI 0.63–0.86), P < .001], and X-ray exposure [1083 vs. 1423 mGy.cm², GMR 0.76 (95% CI 0.62–0.93), P = .009]. There was no significant difference in complication rates between groups (P = .68). IPUS-AVP is superior to CVC in terms of success rate, time to venous access, procedure duration, and radiation exposure. Complication rates were similar between the two groups. Intra-pocket ultrasound-guided axillary vein puncture should be a recommended venous access technique for CIED implantation. Efficacy and safety of intra-pocket ultrasound-guided axillary vein access vs. cephalic vein cutdown for implantation of cardiac electronic devices. CVC, cephalic vein cutdown; IPUS-AVP, intra-pocket ultrasound-guided axillary vein puncture.
- 26 May 2022
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 38 (10) , 1474-1475
In-Stent Use of Intravascular Coronary Lithotripsy for Restenosis and Stent Underexpansion: A Multicentre Experience
- 26 May 2022
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 38 (10) , 1474-1475
In-Stent Use of Intravascular Coronary Lithotripsy for Restenosis and Stent Underexpansion: A Multicentre Experience
- Open Access
- 16 April 2022
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 2 (3) , oeac029
Comorbidities may offset expected improved survival after transcatheter aortic valve replacement
After transcatheter aortic valve replacement (TAVR), cardiovascular and non-cardiovascular comorbidities may offset the survival benefit from the procedure. We aimed to describe the relationships between that benefit and patient comorbidities. The study pooled two European cohorts of patients with severe aortic stenosis (AS-pooled): one with patients who underwent (cohort of AS patients treated by TAVR, N = 233) and another with patients who did not undergo TAVR (cohort of AS patients treated medically; N = 291). The investigators collected the following: calcification prognostic impact (CAPRI) and Charlson scores for cardiovascular and non-cardiovascular comorbidities, activities of daily living (ADL)/instrumental activities of daily living (IADL) scores for frailty as well as routine Society of Thoracic Surgeons (STS) score and Logistic Euroscore. Unlike ADL/IADL scores, CAPRI and Charlson scores were found to be independent predictors of 1-year all-cause death in the AS-pooled cohort, with and without adjustment for STS score or Logistic Euroscore; they were thus retained to define a three-level prognostic scale (good, intermediate, and poor). The survival benefit from TAVR—vs. no TAVR—was stratified according to these three prognosis categories. The beneficial effect of TAVR on 1-year all-cause death was significant in patients with good and intermediate prognosis, hazard ratio (95% confidence interval): 0.36 (0.18; 0.72) and 0.32 (0.15; 0.67). That effect was reduced and not statistically significant in patient with poor prognosis [0.65 (0.22; 1.88)]. The study showed that, beyond a given comorbidity burden (as assessed by CAPRI and Charlson scores), the probability of death within a year was high and poorly reduced by TAVR. This indicates the futility of TAVR in patients in the poor prognosis category. Relationship between prognosis category and the transcatheter aortic valve replacement (TAVR) effect. Prognosis categories were defined using the tertiles of calcification prognostic impact and Charlson scores. The estimates of 1-year all-cause death probabilities in each cohort (cohort of AS patients treated medically and cohort of AS patients treated by TAVR) were obtained using a multivariable Cox regression model. The mortality curves were obtained using an interpolated polynomial of degree 2 based on those estimates. The hatched area indicates the difference in the probability of 1-year death between the two cohorts and illustrates mainly the TAVR effect. While both TAVR and the prognosis category contributed to 1-year all-cause death, the contribution of TAVR was not uniform across the range of prognoses; the poorer was the prognosis category, the lower was the benefit from TAVR.
- 16 April 2022
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 2 (3) , oeac029
Open AccessComorbidities may offset expected improved survival after transcatheter aortic valve replacement
After transcatheter aortic valve replacement (TAVR), cardiovascular and non-cardiovascular comorbidities may offset the survival benefit from the procedure. We aimed to describe the relationships between that benefit and patient comorbidities. The study pooled two European cohorts of patients with severe aortic stenosis (AS-pooled): one with patients who underwent (cohort of AS patients treated by TAVR, N = 233) and another with patients who did not undergo TAVR (cohort of AS patients treated medically; N = 291). The investigators collected the following: calcification prognostic impact (CAPRI) and Charlson scores for cardiovascular and non-cardiovascular comorbidities, activities of daily living (ADL)/instrumental activities of daily living (IADL) scores for frailty as well as routine Society of Thoracic Surgeons (STS) score and Logistic Euroscore. Unlike ADL/IADL scores, CAPRI and Charlson scores were found to be independent predictors of 1-year all-cause death in the AS-pooled cohort, with and without adjustment for STS score or Logistic Euroscore; they were thus retained to define a three-level prognostic scale (good, intermediate, and poor). The survival benefit from TAVR—vs. no TAVR—was stratified according to these three prognosis categories. The beneficial effect of TAVR on 1-year all-cause death was significant in patients with good and intermediate prognosis, hazard ratio (95% confidence interval): 0.36 (0.18; 0.72) and 0.32 (0.15; 0.67). That effect was reduced and not statistically significant in patient with poor prognosis [0.65 (0.22; 1.88)]. The study showed that, beyond a given comorbidity burden (as assessed by CAPRI and Charlson scores), the probability of death within a year was high and poorly reduced by TAVR. This indicates the futility of TAVR in patients in the poor prognosis category. Relationship between prognosis category and the transcatheter aortic valve replacement (TAVR) effect. Prognosis categories were defined using the tertiles of calcification prognostic impact and Charlson scores. The estimates of 1-year all-cause death probabilities in each cohort (cohort of AS patients treated medically and cohort of AS patients treated by TAVR) were obtained using a multivariable Cox regression model. The mortality curves were obtained using an interpolated polynomial of degree 2 based on those estimates. The hatched area indicates the difference in the probability of 1-year death between the two cohorts and illustrates mainly the TAVR effect. While both TAVR and the prognosis category contributed to 1-year all-cause death, the contribution of TAVR was not uniform across the range of prognoses; the poorer was the prognosis category, the lower was the benefit from TAVR.
- 23 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 23 (5) , e241
Inferior ST-segment elevation myocardial infarction secondary to spontaneous type A aortic intramural haematoma
- 23 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 23 (5) , e241
Inferior ST-segment elevation myocardial infarction secondary to spontaneous type A aortic intramural haematoma